Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, Bari, 70124, Italy.
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy.
Immunotherapy. 2023 Feb;15(2):117-126. doi: 10.2217/imt-2022-0023. Epub 2023 Jan 25.
We performed a meta-analysis to assess the relative risk (RR) of all-grade and grade 3-4 hypertransaminasemia in studies comparing immune-based combinations with sunitinib in treatment-naive patients with advanced renal cell carcinoma. Outcomes of interest included all-grade and grade 3-4 hypertransaminasemia measured as RRs and 95% confidence intervals (CIs). RRs for all-grade hypertransaminasemia were 1.73 (95% CI: 1.25-2.4) and 1.63 (95% CI: 1.25-2.12) in patients receiving immunocombinations and sunitinib, respectively. The pooled RRs for grade 3-4 hypertransaminasemia were 3.24 and 3.04 in patients treated with immunocombinations or sunitinib. Immune-based combinations were associated with higher hypertransaminasemia risk. Physicians should pay attention to these common but overlooked events. Careful monitoring of tolerability remains a crucial need.
我们进行了一项荟萃分析，以评估在比较免疫联合治疗与舒尼替尼治疗初治晚期肾细胞癌患者时，所有级别和 3-4 级高转氨酶血症的相对风险（RR）。感兴趣的结局包括所有级别和 3-4 级高转氨酶血症，以 RR 和 95%置信区间（CI）表示。接受免疫联合治疗和舒尼替尼治疗的患者的所有级别高转氨酶血症 RR 分别为 1.73（95%CI：1.25-2.4）和 1.63（95%CI：1.25-2.12）。免疫联合治疗或舒尼替尼治疗患者的 3-4 级高转氨酶血症的汇总 RR 分别为 3.24 和 3.04。免疫联合治疗与高转氨酶血症风险增加相关。医生应注意这些常见但被忽视的事件。仔细监测耐受性仍然是一个关键需求。
Expert Rev Gastroenterol Hepatol. 2021-10
Target Oncol. 2022-3
Zotero 插件